open access

Vol 2, No 4 (2001): Practical Diabetology
Original articles (submitted)
Published online: 2001-11-19
Get Citation

Tumor necrosis factor alpha (TNF- < font face=

Grzegorz Dzida, Andrzej Biłan, Janusz Hanzlik
Diabetologia Praktyczna 2001;2(4):267-272.

open access

Vol 2, No 4 (2001): Practical Diabetology
Original articles (submitted)
Published online: 2001-11-19

Abstract

INTRODUCTION. Tumor necrosis factor a (TNF-a) is a cytokine which may contribute to the pathogenesis of insulin resistance. This resistance to insulin action plays a key role in type 2 diabetes. The aim of the study was the assessment of the association of TNF-a gene polymorphism with type 2 diabetes in Polish population.
MATERIAL AND METHODS. G-308A polymorphism in the promoter region of TNF-a gene was detected using polymerase chain reaction and restriction fragments length polymorphism (PCR-RFLP) method. Studied subjects were 172 patients with type 2 diabetes. Control group consisted of 172 healthy individuals with normal glucose tolerance, age and sex matched to study group.
RESULTS. TNF2 genotype occurred more frequently in healthy individuals when compared to diabetics (0.29 vs. 0.20). Diabetic TNF2 genotype bearers clinical chacharacteristics did not differ substantially to this of diabetics with TNF1 genotype. The only important difference was higher frequency of arterial hypertension in TNF2 diabetic patients comparing to normotensive diabetic individuals. There was statistically important difference in TNF2 frequency, which was substantially lower among normotensive diabetics than among diabetics with hypertension and control subjects (p = 0.011).
CONCLUSIONS. TNF2 genotype seems not to be associated with susceptibility to type 2 diabetes but in contrary might be protective against the disease. TNF2 variant is a risk factor of arterial hypertension accompanying type 2 diabetes in study population.

Abstract

INTRODUCTION. Tumor necrosis factor a (TNF-a) is a cytokine which may contribute to the pathogenesis of insulin resistance. This resistance to insulin action plays a key role in type 2 diabetes. The aim of the study was the assessment of the association of TNF-a gene polymorphism with type 2 diabetes in Polish population.
MATERIAL AND METHODS. G-308A polymorphism in the promoter region of TNF-a gene was detected using polymerase chain reaction and restriction fragments length polymorphism (PCR-RFLP) method. Studied subjects were 172 patients with type 2 diabetes. Control group consisted of 172 healthy individuals with normal glucose tolerance, age and sex matched to study group.
RESULTS. TNF2 genotype occurred more frequently in healthy individuals when compared to diabetics (0.29 vs. 0.20). Diabetic TNF2 genotype bearers clinical chacharacteristics did not differ substantially to this of diabetics with TNF1 genotype. The only important difference was higher frequency of arterial hypertension in TNF2 diabetic patients comparing to normotensive diabetic individuals. There was statistically important difference in TNF2 frequency, which was substantially lower among normotensive diabetics than among diabetics with hypertension and control subjects (p = 0.011).
CONCLUSIONS. TNF2 genotype seems not to be associated with susceptibility to type 2 diabetes but in contrary might be protective against the disease. TNF2 variant is a risk factor of arterial hypertension accompanying type 2 diabetes in study population.
Get Citation

Keywords

tumor necrosis factor-a; insulin resistance; diabetes type 2; arterial hypertension; genetic polymorphism

About this article
Title

Tumor necrosis factor alpha (TNF-

Journal

Clinical Diabetology

Issue

Vol 2, No 4 (2001): Practical Diabetology

Pages

267-272

Published online

2001-11-19

Bibliographic record

Diabetologia Praktyczna 2001;2(4):267-272.

Keywords

tumor necrosis factor-a
insulin resistance
diabetes type 2
arterial hypertension
genetic polymorphism

Authors

Grzegorz Dzida
Andrzej Biłan
Janusz Hanzlik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl